231 related articles for article (PubMed ID: 35909944)
1. Enriched circulating and tumor-resident TGF-β
Harris RJ; Willsmore Z; Laddach R; Crescioli S; Chauhan J; Cheung A; Black A; Geh JLC; MacKenzie Ross AD; Healy C; Tsoka S; Spicer J; Lacy KE; Karagiannis SN
Oncoimmunology; 2022; 11(1):2104426. PubMed ID: 35909944
[TBL] [Abstract][Full Text] [Related]
2. Promoted Generation of T Helper 1-Like Regulatory T Cells After Transient Middle Cerebral Artery Occlusion in Type-2 Diabetic Mice.
Jian L; Hu Y; Gao M; Shu L
Immunol Invest; 2023 Nov; 52(4):482-498. PubMed ID: 37076315
[TBL] [Abstract][Full Text] [Related]
3. Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destruction.
Niu J; Jiang C; Li C; Liu L; Li K; Jian Z; Gao T
Cancer Immunol Immunother; 2011 Aug; 60(8):1109-18. PubMed ID: 21547596
[TBL] [Abstract][Full Text] [Related]
4. Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4
Polanczyk MJ; Walker E; Haley D; Guerrouahen BS; Akporiaye ET
J Transl Med; 2019 Jul; 17(1):219. PubMed ID: 31288845
[TBL] [Abstract][Full Text] [Related]
5. Decreased suppression of CD8
Giri PS; Dwivedi M; Begum R
Exp Dermatol; 2020 Aug; 29(8):759-775. PubMed ID: 32682346
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulation of human CD19
Hong M; Liao Y; Liang J; Chen X; Li S; Liu W; Gao C; Zhong Z; Kong D; Deng J; Zhang J; Pan G
Hum Immunol; 2019 Oct; 80(10):863-870. PubMed ID: 31262519
[TBL] [Abstract][Full Text] [Related]
7. CD4
Kindlund B; Sjöling Å; Yakkala C; Adamsson J; Janzon A; Hansson LE; Hermansson M; Janson P; Winqvist O; Lundin SB
Gastric Cancer; 2017 Jan; 20(1):116-125. PubMed ID: 26782287
[TBL] [Abstract][Full Text] [Related]
8. ICOS
Nagase H; Takeoka T; Urakawa S; Morimoto-Okazawa A; Kawashima A; Iwahori K; Takiguchi S; Nishikawa H; Sato E; Sakaguchi S; Mori M; Doki Y; Wada H
Int J Cancer; 2017 Feb; 140(3):686-695. PubMed ID: 27756099
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
[TBL] [Abstract][Full Text] [Related]
10. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
11. The Curcumin Analog GO-Y030 Controls the Generation and Stability of Regulatory T Cells.
MaruYama T; Kobayashi S; Nakatsukasa H; Moritoki Y; Taguchi D; Sunagawa Y; Morimoto T; Asao A; Jin W; Owada Y; Ishii N; Iwabuchi Y; Yoshimura A; Chen W; Shibata H
Front Immunol; 2021; 12():687669. PubMed ID: 34248973
[TBL] [Abstract][Full Text] [Related]
12. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice.
Carrier Y; Yuan J; Kuchroo VK; Weiner HL
J Immunol; 2007 Jan; 178(1):179-85. PubMed ID: 17182553
[TBL] [Abstract][Full Text] [Related]
13. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
Yu Y; Huang R; Zong X; He X; Mo W
BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
[TBL] [Abstract][Full Text] [Related]
14. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
[TBL] [Abstract][Full Text] [Related]
15. HSP70 enhances immunosuppressive function of CD4(+)CD25(+)FoxP3(+) T regulatory cells and cytotoxicity in CD4(+)CD25(-) T cells.
Wachstein J; Tischer S; Figueiredo C; Limbourg A; Falk C; Immenschuh S; Blasczyk R; Eiz-Vesper B
PLoS One; 2012; 7(12):e51747. PubMed ID: 23300563
[TBL] [Abstract][Full Text] [Related]
16. Loss of regulatory characteristics in CD4
Bian LQ; Mao L; Bi Y; Zhou SW; Chen ZD; Wen J; Shi J; Wang L
APMIS; 2017 Dec; 125(12):1108-1116. PubMed ID: 28913840
[TBL] [Abstract][Full Text] [Related]
17. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
18. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H
Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338
[TBL] [Abstract][Full Text] [Related]
19. [
Qian-Qian Q; Xiao-Fan W; Li-Na Z; Li-Yang D; Ji-Feng Z; Xiao-Jun C; Zhi-Peng X; Ya-Lin L; Feng L; Sha Z; Chuan S
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2018 Feb; 30(1):42-46. PubMed ID: 29536706
[TBL] [Abstract][Full Text] [Related]
20. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
Budhu S; Schaer DA; Li Y; Toledo-Crow R; Panageas K; Yang X; Zhong H; Houghton AN; Silverstein SC; Merghoub T; Wolchok JD
Sci Signal; 2017 Aug; 10(494):. PubMed ID: 28851824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
